<p>There was no significant difference in body weight of SOD1-G93A mice between the different diet groups either before treatment started (Baseline), at presymptomatic stage (before neurological score 1) and at endpoint of the study. All data are mean ± SEM.</p
<p>The difference in neurological score was significant between the control group (SD) and KD group ...
[A] Body Weight: Body weight was measured 1 wk prior to starting the feeding trial while all mice we...
<p>(A) Assessments of body weight and (B) food intake in APP+PS1, Tg4510 and nontransgenic mice on e...
<p>(A) Motor signs (hind limb tremors) were measured with the clinical scoring system (see methods)....
<p><b>Effect of treatments on body weight.</b> (<b>A</b>) <i>mdx</i> mice received no treatment (N =...
<p>There were 10 mice in each diet group. (A) *, stearic acid vs. all other diets, p<0.01. #, low fa...
<p>Body weight was measured through the experiments in both SD and PD groups (N = 8 for SD, N = 9 fo...
<p>Mice were treated with 50/kg SU5416 or vehicle twice per week for 3 weeks. Mice were weighed twic...
<p>A, Weight of female mice. B, Weight of male mice. Disease onset was calculated retrospectively as...
<p>Data are given as means ± SEM, for all figures # indicates significant differences to pre trainin...
<p>(A) The SOD-1 (G93A)<sup>PS</sup> mice (n = 8) have a delayed onset of weight decrease when compa...
<p>Group average change from initial body weight (top panels) and neurological disease severity scor...
<p>Summary of mean body weights of mice at the beginning of treatment and at the termination of the ...
All mice started at above average weight for mice of this background strain and gender. Weight incre...
<p>(A) Control and MB-treated (3, 10, 30 and 100 mg oral per kg body weight per day) SOD1<sup>G93A</...
<p>The difference in neurological score was significant between the control group (SD) and KD group ...
[A] Body Weight: Body weight was measured 1 wk prior to starting the feeding trial while all mice we...
<p>(A) Assessments of body weight and (B) food intake in APP+PS1, Tg4510 and nontransgenic mice on e...
<p>(A) Motor signs (hind limb tremors) were measured with the clinical scoring system (see methods)....
<p><b>Effect of treatments on body weight.</b> (<b>A</b>) <i>mdx</i> mice received no treatment (N =...
<p>There were 10 mice in each diet group. (A) *, stearic acid vs. all other diets, p<0.01. #, low fa...
<p>Body weight was measured through the experiments in both SD and PD groups (N = 8 for SD, N = 9 fo...
<p>Mice were treated with 50/kg SU5416 or vehicle twice per week for 3 weeks. Mice were weighed twic...
<p>A, Weight of female mice. B, Weight of male mice. Disease onset was calculated retrospectively as...
<p>Data are given as means ± SEM, for all figures # indicates significant differences to pre trainin...
<p>(A) The SOD-1 (G93A)<sup>PS</sup> mice (n = 8) have a delayed onset of weight decrease when compa...
<p>Group average change from initial body weight (top panels) and neurological disease severity scor...
<p>Summary of mean body weights of mice at the beginning of treatment and at the termination of the ...
All mice started at above average weight for mice of this background strain and gender. Weight incre...
<p>(A) Control and MB-treated (3, 10, 30 and 100 mg oral per kg body weight per day) SOD1<sup>G93A</...
<p>The difference in neurological score was significant between the control group (SD) and KD group ...
[A] Body Weight: Body weight was measured 1 wk prior to starting the feeding trial while all mice we...
<p>(A) Assessments of body weight and (B) food intake in APP+PS1, Tg4510 and nontransgenic mice on e...